Search
Parsaclisib
go.drugbank.com/drugs/DB14867InvestigationalParsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
PF-04620110
go.drugbank.com/drugs/DB14887InvestigationalPF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
Spartalizumab
go.drugbank.com/drugs/DB14892InvestigationalSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
Bazlitoran
go.drugbank.com/drugs/DB14990InvestigationalBazlitoran is under investigation in clinical trial NCT02092909 (Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia).
Voruciclib
go.drugbank.com/drugs/DB15157InvestigationalVoruciclib is under investigation in clinical trial NCT03547115 (A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML).
Bevifimod
go.drugbank.com/drugs/DB15301InvestigationalBevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).
Lorukafusp alfa
go.drugbank.com/drugs/DB15443InvestigationalLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Narazaciclib
go.drugbank.com/drugs/DB19038InvestigationalNarazaciclib is under investigation in clinical trial NCT06351644 (On 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed And/or Refractory Multiple Myeloma).
Zelenirstat
go.drugbank.com/drugs/DB15567InvestigationalZelenirstat (PCLX-001) is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals](https://pacylex.com).
Bioymifi
go.drugbank.com/drugs/DB17493ExperimentalBioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-depen...